Maplight Therapeutics, Inc. (NASDAQ:MPLT – Free Report) – Equities research analysts at Lifesci Capital lowered their Q2 2026 earnings per share estimates for Maplight Therapeutics in a research note issued to investors on Friday, May 15th. Lifesci Capital analyst F. Brisebois now anticipates that the company will earn ($1.38) per share for the quarter, down from their prior forecast of ($1.02). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Maplight Therapeutics’ current full-year earnings is ($4.04) per share. Lifesci Capital also issued estimates for Maplight Therapeutics’ Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.45) EPS and FY2026 earnings at ($5.56) EPS.
Other analysts have also issued reports about the company. Weiss Ratings began coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating for the company. HC Wainwright began coverage on Maplight Therapeutics in a report on Monday, May 4th. They set a “buy” rating and a $45.00 price objective for the company. Needham & Company LLC began coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating and a $37.00 price objective for the company. Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Maplight Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.43.
Maplight Therapeutics Trading Down 7.8%
Shares of NASDAQ:MPLT opened at $26.50 on Tuesday. Maplight Therapeutics has a 1 year low of $12.24 and a 1 year high of $33.28. The stock’s fifty day moving average price is $24.41. The stock has a market capitalization of $1.13 billion and a price-to-earnings ratio of -0.67.
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43).
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Strs Ohio bought a new position in Maplight Therapeutics in the 4th quarter worth approximately $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $93,000. MetLife Investment Management LLC acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $172,000. Finally, Walleye Capital LLC acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $205,000.
Insider Buying and Selling
In other news, insider Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $691,735.52. Following the completion of the transaction, the insider owned 350,497 shares in the company, valued at approximately $10,080,293.72. The trade was a 6.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher A. Kroeger sold 118,235 shares of Maplight Therapeutics stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the completion of the transaction, the chief executive officer owned 1,394,094 shares of the company’s stock, valued at $37,905,415.86. This trade represents a 7.82% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have purchased 25,000 shares of company stock valued at $441,168 and have sold 509,439 shares valued at $14,339,878. 3.80% of the stock is currently owned by insiders.
Maplight Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Articles
- Five stocks we like better than Maplight Therapeutics
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
